LEAWOOD, Kan., Feb. 22, 2017 /PRNewswire/ -- Aratana
Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company
focused on the licensing, development and commercialization of
innovative biopharmaceutical products for companion animals, will
host a live conference call on Tuesday,
March 14, 2017 at 8:30 a.m. ET
to discuss financial results from the fourth quarter and full year
ended December 31, 2016.
Interested participants and investors may access the audio
webcast or use the conference call dial-in:
1 (866) 364-3820 (U.S.)
1 (855) 669-9657 (Canada)
1 (412) 902-4210 (International)
A replay of the fourth quarter and full year 2016 results
teleconference will be available the same day of the event by
approximately 11 a.m. ET and an audio
webcast will be accessible for 90 days in the Aratana Investor
Room. For a replay of the call, use the below dial-in and
conference ID 10101834:
1 (877) 344-7529 (U.S.)
1 (855) 669-9658 (Canada)
1 (412) 317-0088 (International)
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on licensing, developing and
commercializing innovative biopharmaceutical products for companion
animals. Aratana believes that it can leverage the investment in
the human biopharmaceutical industry to bring therapeutics to pets
in a capital and time efficient manner. The Company's pipeline
includes therapeutic candidates targeting pain, inappetence,
cancer, viral diseases, allergy and other serious medical
conditions. Aratana believes the development and
commercialization of these therapeutics will permit veterinarians
and pet owners to manage pets' medical needs safely and
effectively, resulting in longer and improved quality of life for
pets. For more information, please visit www.aratana.com.
Contacts
For investor inquires:
Craig Tooman
ctooman@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/aratana-therapeutics-to-report-fourth-quarter-and-full-year-2016-financial-results-300411082.html
SOURCE Aratana Therapeutics, Inc.